Skip to main
  1. Stocks
  2. CME Group
  3. Forecast
CME

CME Group (CME) Stock Forecast & Price Target

CME Group (CME) Analyst Ratings

Based on 13 analyst ratings
Buy
Strong Buy 15%
Buy 46%
Hold 31%
Sell 8%
Strong Sell 0%

Bulls say

CME Group is well positioned by its dominant derivatives franchise, built through the 2007 CBOT merger, the 2008 Nymex acquisition, and the 2018 NEX deal, which broadened its reach into cash foreign exchange, fixed-income trading, and collateral optimization while preserving high incremental margins. The latest quarter reinforced that strength with record revenues of $1.74 billion, adjusted EPS of $3.02, market data and info services fees up 20% YoY, ADV up 16% YoY, and open interest at 128 million contracts, showing durable engagement across six asset classes. Its outlook is further supported by pricing power, a 27% stake in S&P Dow Jones Indices, accelerating product innovation including 368 new products year to date, and optionality from compute futures, 24/7 trading, and single stock futures, while management’s confidence in the CFTC litigation reduces a key regulatory overhang.

Bears say

CME Group is facing a softer fundamental backdrop as decelerating Average Daily Volume and weaker Revenue per Contract trends could pressure trading revenue and operating leverage. Its core franchise is also exposed to macro headwinds, including lower short-term interest rate expectations, a flatter forward yield curve, and widening credit spreads, which can reduce hedging demand across rates, credit, and energy. Competitive threats from FMX, CBOE, and ICE, along with possible market share erosion, poor integration execution after the 2018 NEX deal, and adverse regulatory changes, reinforce a cautious outlook.

CME Group (CME) has been analyzed by 13 analysts, with a consensus rating of Buy. 15% of analysts recommend a Strong Buy, 46% recommend Buy, 31% suggest Holding, 8% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of CME Group and is not a guaranteed prediction by Public.com or investment advice.

CME Group (CME) Analyst Forecast & Price Prediction

Get the latest CME Group (CME) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in CME Group (CME)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About CME Group (CME) Forecast

Analysts have given CME Group (CME) a Buy based on their latest research and market trends.

According to 13 analysts, CME Group (CME) has a Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $313.08, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $313.08, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

CME Group (CME)


CME Group (CME) Analyst Forecast & Price Prediction

Get the latest CME Group (CME) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in CME Group (CME)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover CME stock data and trends